P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847148.78233.c8 |
| _version_ | 1827336325702877184 |
|---|---|
| author | V. Pullarkat A. Cruz-Chacon S. Gangatharan A. Melnyk G. A. Palumbo M. Bellini S. K. Tantravahi Q. Qin J. Potluri P. Vachhani |
| author_facet | V. Pullarkat A. Cruz-Chacon S. Gangatharan A. Melnyk G. A. Palumbo M. Bellini S. K. Tantravahi Q. Qin J. Potluri P. Vachhani |
| author_sort | V. Pullarkat |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:28:49Z |
| format | Article |
| id | doaj.art-3bf8de27010e4c3899fd36b3cf38a0a3 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:28:49Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-3bf8de27010e4c3899fd36b3cf38a0a32024-03-02T06:40:53ZengWileyHemaSphere2572-92412022-06-01696096110.1097/01.HS9.0000847148.78233.c8202206003-00960P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITYV. Pullarkat0A. Cruz-Chacon1S. Gangatharan2A. Melnyk3G. A. Palumbo4M. Bellini5S. K. Tantravahi6Q. Qin7J. Potluri8P. Vachhani91 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States of America2 Hospital Centro Comprensivo de Cancer Universidad de Puerto Rico, San Juan, Puerto Rico3 Department of Haematology, Fiona Stanley Hospital, University of Western Australia, Perth, Western Australia, Australia4 Texas Oncology-Abilene, Abilene, TX, United States of America5 Dipartimento di Science Mediche Chirurgiche e Tecnologie Avanzate “GF Ingrassia”, Università degli Studi di Catania, Catania6 ASST Papa Giovanni XXIII, Bergamo, Italy7 University of Utah and Huntsman Cancer Institute, Salt Lake City, UT8 AbbVie Inc., North Chicago, IL8 AbbVie Inc., North Chicago, IL9 O’Neal Comprehensive Cancer Center at UAB, Birmingham, AL, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847148.78233.c8 |
| spellingShingle | V. Pullarkat A. Cruz-Chacon S. Gangatharan A. Melnyk G. A. Palumbo M. Bellini S. K. Tantravahi Q. Qin J. Potluri P. Vachhani P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY HemaSphere |
| title | P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY |
| title_full | P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY |
| title_fullStr | P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY |
| title_full_unstemmed | P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY |
| title_short | P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY |
| title_sort | p1070 navitoclax monotherapy in patients with myelofibrosis previously treated with jak 2 inhibitors safety and tolerability |
| url | http://journals.lww.com/10.1097/01.HS9.0000847148.78233.c8 |
| work_keys_str_mv | AT vpullarkat p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability AT acruzchacon p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability AT sgangatharan p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability AT amelnyk p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability AT gapalumbo p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability AT mbellini p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability AT sktantravahi p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability AT qqin p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability AT jpotluri p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability AT pvachhani p1070navitoclaxmonotherapyinpatientswithmyelofibrosispreviouslytreatedwithjak2inhibitorssafetyandtolerability |